文献速递心血管PETCTMR

肥厚型心肌病18F-FAPI PET/CT心肌活性与心脏性猝死风险

Myocardial Activity at 18F-FAPI PET/CT and Risk for Sudden Cardiac Death in Hypertrophic Cardiomyopathy.
PubMed 文献 · Radiology · 2022-10-11

结果显示患者心肌FAPI活性强烈且不均匀,高于健康对照,且FAPI总量与5年SCD风险评分正相关。

要点

  • HCM患者左室心肌FAPI活性强烈且不均匀,靶本比中位数8.8,显著高于健康对照的2.1。
  • FAPI活性节段数多于肥厚节段数(中位数14 vs 5),84%的非肥厚节段也显示FAPI活性。

关键影像表现/征象

  • HCM患者左室心肌显示强烈且不均匀的FAPI活性,靶本比中位数8.8,健康对照为2.1(P<.001)。
  • HCM中FAPI活性节段数多于肥厚节段数(中位数14 vs 5,P<.001),84%的非肥厚节段显示FAPI活性。
  • FAPI活性程度与5年SCD风险评分正相关(r=0.32;P=.03)。

临床应用与阅片要点

  • 18F-FAPI PET/CT可用于评估HCM心肌纤维母细胞活化,FAPI活性范围超出肥厚节段,提示应关注非肥厚区域的FAPI摄取。
  • FAPI总量与5年SCD风险评分相关,可能辅助风险分层,但需结合其他临床指标。

局限性

  • FAPI活性与SCD风险的关联为相关性分析,非因果推断。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Background Myocardial fibrosis contributes to adverse cardiovascular events in hypertrophic cardiomyopathy (HCM). Purpose To explore the characteristics of cardiac fibroblast activation protein inhibitor (FAPI) PET/CT imaging and its relationship with the risk of sudden cardiac death (SCD) in HCM. Materials and Methods In this prospective study from July 2021 to January 2022, participants with HCM and healthy control participants underwent cardiac fluorine 18 (18F)-labeled FAPI PET/CT imaging. Myocardial FAPI activity was quantified as intensity (target-to-background uptake ratio), extent (the percent of FAPI-avid myocardium of the left ventricle [LV]), and amount (the percent of FAPI-avid myocardium of LV × target-to-background ratio). Regional wall thickness was analyzed at cardiac MRI. The 5-year SCD risk score was calculated from the 2014 European Society of Cardiology guidelines. Univariable and multivariable linear regression analyses were used to identify factors related to the FAPI amount. The correlation between FAPI amount and 5-year SCD risk was explored. Results Fifty study participants with HCM (mean age, 43 years ± 13 [SD]; 32 men) and 22 healthy control participants (mean age, 45 years ± 17; 14 men) were included. All participants with HCM had intense and inhomogeneous cardiac FAPI activity in the LV myocardium that was higher than that in healthy control participants (median target-to-background ratio, 8.8 vs 2.1, respectively; P < .001). In HCM, more segments with FAPI activity were detected than the number of hypertrophic segments (median, 14 vs five, respectively; P < .001); 84% of nonhypertrophic segments showed FAPI activity. Log-transformed FAPI amount had a positive relationship with log-transformed N-terminal probrain natriuretic peptide, high-sensitive troponin I, and left atrial diameter and a negative relationship with LV ejection fraction z-score. Degree of FAPI activity positively correlated with the 5-year SCD risk score (r = 0.32; P = .03). Conclusion Fibroblast activation protein inhibitor (FAPI) PET/CT imaging indicated intense and heterogeneous activity in hypertrophic cardiomyopathy, and FAPI uptake was associated with 5-year risk of sudden cardiac death. © RSNA, 2022 Online supplemental material is available for this article.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Wang, Wang, Wang, et al. Myocardial Activity at 18F-FAPI PET/CT and Risk for Sudden Cardiac Death in Hypertrophic Cardiomyopathy. Radiology. 2022. PMID: 36219116. doi:10.1148/radiol.221052

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。